Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Novo Nordisk-Minnesota deal to settle insulin lawsuit approved
A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that ...
Novo Nordisk Stock (NVO) Plunges as It Shells Out $2 Billion on Chinese Weight Drug
Novo Nordisk (NVO) just agreed to shell out up to $2 billion for the global rights to a Chinese weight-loss drug—and the market wasn’t ...
Medscape9d
Should ‘Time in Tight Range’ Be the Primary Diabetes Goal?
ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.